509079 Stock Overview
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Gufic Biosciences Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹283.15 |
52 Week High | ₹364.00 |
52 Week Low | ₹181.60 |
Beta | 0.82 |
1 Month Change | -10.27% |
3 Month Change | -10.25% |
1 Year Change | 49.89% |
3 Year Change | 143.88% |
5 Year Change | 278.54% |
Change since IPO | 1,652.17% |
Recent News & Updates
Recent updates
Shareholder Returns
509079 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | -4.0% | 2.7% | 2.5% |
1Y | 49.9% | 63.9% | 47.3% |
Return vs Industry: 509079 underperformed the Indian Pharmaceuticals industry which returned 63.9% over the past year.
Return vs Market: 509079 exceeded the Indian Market which returned 47.3% over the past year.
Price Volatility
509079 volatility | |
---|---|
509079 Average Weekly Movement | 4.6% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 509079's share price has been volatile over the past 3 months.
Volatility Over Time: 509079's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1970 | 1,628 | Pranav Choksi | https://www.gufic.com |
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments.
Gufic Biosciences Limited Fundamentals Summary
509079 fundamental statistics | |
---|---|
Market cap | ₹28.39b |
Earnings (TTM) | ₹841.95m |
Revenue (TTM) | ₹7.85b |
33.7x
P/E Ratio3.6x
P/S RatioIs 509079 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
509079 income statement (TTM) | |
---|---|
Revenue | ₹7.85b |
Cost of Revenue | ₹3.91b |
Gross Profit | ₹3.93b |
Other Expenses | ₹3.09b |
Earnings | ₹841.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 30, 2024
Earnings per share (EPS) | 8.40 |
Gross Margin | 50.13% |
Net Profit Margin | 10.73% |
Debt/Equity Ratio | 91.8% |
How did 509079 perform over the long term?
See historical performance and comparison